Could Sellas Life Sciences Group Inc (NASDAQ:SLS) Change Direction After More Shorts?

The stock of Sellas Life Sciences Group Inc (NASDAQ:SLS) registered an increase of 9.61% in short interest. SLS’s total short interest was 2.68M shares in April as published by FINRA. Its up 9.61% from 2.45M shares, reported previously. With 301,000 shares average volume, it will take short sellers 9 days to cover their SLS’s short positions. The short interest to Sellas Life Sciences Group Inc’s float is 15.2%.

The stock decreased 2.94% or $0.03 during the last trading session, reaching $0.99. About 134,456 shares traded. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) has declined 72.00% since April 17, 2018 and is downtrending. It has underperformed by 76.37% the S&P500.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company has market cap of $22.95 million. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It currently has negative earnings. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia.

More notable recent SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) news were published by: Globenewswire.com which released: “SELLAS Life Sciences Announces Closing of $24.2 Million Public Offering – GlobeNewswire” on July 16, 2018, also Globenewswire.com with their article: “SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin┬« at the 2018 San Antonio Breast Cancer Symposium – GlobeNewswire” published on November 30, 2018, Globenewswire.com published: “SELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton, Ltd. for $6.6 Million Payment by JGB – GlobeNewswire” on November 09, 2018. More interesting news about SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) were released by: Globenewswire.com and their article: “SELLAS Life Sciences to Present at the 2018 Cantor Global Healthcare Conference – GlobeNewswire” published on September 24, 2018 as well as Globenewswire.com‘s news article titled: “Bio-on board of directors approves Draft Budget and IAS/IFRS Consolidated Financial Statement at 31 December 2018 – GlobeNewswire” with publication date: March 30, 2019.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.